C1QBP and central nervous system cancer: The ability of p32 CAR T cells to recognize and eliminate glioma cells in different phenotypic/differentiated states provides an advantage to this strategy over the existing conventional therapies and the possibility of combining these therapeutic approaches for the treatment of GBM.